Synonyms: AZD 1656 | AZD-1656
Compound class:
Synthetic organic
Comment: AZD1656 activates glucokinase (GCK; P35557). AZD1656 was developed as a potential treatment for diabetes. This compound is included in AstaZeneca's Open Innovation Pharmacology Toolbox.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
AZD1656 has been advanced to clinical evaluation to determine efficacy as an anti-diabetes (T2DM) drug. |
Mechanism Of Action and Pharmacodynamic Effects |
Treatment with AZD1565 rapidly and dose-dependently reduces plasma glucose levels in in vivo animal models, and as determined in human subjects [2]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05216172 | AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce | Phase 2 Interventional | Queen Mary University of London | ||
NCT04516759 | AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 | Phase 2 Interventional | St George Street Capital |